{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T04:17:27Z","timestamp":1791778647659,"version":"4.3.4"},"reference-count":10,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1016\/j.leukres.2009.08.005","type":"journal-article","created":{"date-parts":[[2009,9,10]],"date-time":"2009-09-10T09:44:34Z","timestamp":1252575874000},"page":"714-717","source":"Crossref","is-referenced-by-count":30,"title":["Determination of imatinib plasma levels in patients with chronic myeloid leukemia by high performance liquid chromatography\u2013ultraviolet detection and liquid chromatography\u2013tandem mass spectrometry: Methods\u2019 comparison"],"prefix":"10.1016","volume":"34","author":[{"given":"Abdalla","family":"Awidi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isam I.","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naji","family":"Najib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razan","family":"Mefleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bothainah","family":"Tarawneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2009.08.005_bib1","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2007-07-103523","article-title":"Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment","volume":"111","author":"Hochhaus","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.08.005_bib2","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.leukres.2009.08.005_bib3","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1182\/blood.V101.6.2368","article-title":"MDR1 gene over expression confers resistance to imatinib mesylate in leukemia cell line models","volume":"101","author":"Mahon","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.08.005_bib4","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.08.005_bib5","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.08.005_bib6","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S1570-0232(01)00611-0","article-title":"High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry","volume":"768","author":"Bakhtiar","year":"2002","journal-title":"J Chromatogr B"},{"issue":"6","key":"10.1016\/j.leukres.2009.08.005_bib7","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0731-7085(02)00080-8","article-title":"Quantification of the anti-leukemia drug STI571 (Gleevec) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry","volume":"28","author":"Bakhtiar","year":"2002","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.leukres.2009.08.005_bib8","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00280-003-0741-6","article-title":"Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588","volume":"53","author":"le Coutre","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.leukres.2009.08.005_bib9","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jchromb.2004.01.006","article-title":"Determination of imatinib (Gleevec\u00ae) in human plasma by solid-phase extraction\u2013liquid chromatography\u2013ultraviolet absorbance detection","volume":"803","author":"Widmer","year":"2004","journal-title":"J Chromatogr B"},{"key":"10.1016\/j.leukres.2009.08.005_bib10","unstructured":"Guidance for Industry, Bioanalytical Method Validation, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); May 2001."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212609004123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212609004123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T08:20:55Z","timestamp":1545034855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212609004123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S0145212609004123"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2009.08.005","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}